UNSPSC 51123709: Berlafenone

This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4MYE3XA3GV. European Medicines Agency schedules Berlafenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05781MIG. Berlafenone generally arises in the molecular formula C19H25NO2.

UNSPSC 51123709 Berlafenone is a Commodity code tracking pharmaceutical procurement by state and local governments, though the recent opportunities show state and local agencies buying a broader range of medications and pharmaceutical distribution services rather than berlafenone specifically. The City of Tampa's sealed-bid procurement for Advanced Life Support Medications (IFB 26P00188) exemplifies the direct-supply model: Tampa Fire Rescue requires four specific emergency medication line items totaling over 4,500 units annually at an estimated contract value of $40,000. The Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products reflect larger-scale, systemwide procurement approaches in which state health agencies and cooperative purchasing vehicles establish framework agreements with manufacturers or distributors to serve multiple jurisdictions and facilities. Issuing bodies under this code span city fire and EMS departments, state health and human services commissions, and multistate cooperative purchasing alliances; Florida and Texas show active recent procurement, and MMCAP's Minnesota-administered vehicle serves Oregon and other participating states.

The Tampa opportunity closed April 8, 2026, with a one-year contract term renewable for two additional years plus three 30-day unilateral extensions, firm pricing inclusive of freight to Tampa, nine-month minimum shelf life on delivery, and a 5 percent bid discount for Small Local Business Enterprise subcontractors. The MMCAP RFP (due March 26, 2026) requires manufacturers to supply generic pharmaceuticals through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) with cGMP and Drug Supply Chain Security Act certification, pricing submitted in multiple formats (flat, net, WAC-minus), $5 million general liability and $2 million network security insurance, and compliance with performance penalties of $200–$1,500 per violation; the agreement runs two years effective July 1, 2026, with optional extensions. The Texas HHS RFI (closed April 3, 2026) explores direct contracting without pharmacy benefit manager intermediaries, signaling state interest in direct manufacturer relationships for prescription programs. Geographic activity centers on Florida, Texas, and the Minnesota-led multistate cooperative, with pharmaceutical supply supporting emergency medical services, state employee and Medicaid benefit programs, and affiliated state and local facilities.